

Reference number
2055-A

SPECIALTY GUIDELINE MANAGEMENT

LUMIZYME (alglucosidase alfa)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Lumizyme is indicated for patients with Pompe disease (acid alpha-glucosidase [GAA] deficiency).

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis.
- B. Continuation requests: chart notes documenting a positive response to therapy.

III. CRITERIA FOR INITIAL APPROVAL

Pompe disease

Authorization of 12 months may be granted for treatment of Pompe disease when the diagnosis of Pompe disease was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, cardiorespiratory function, decrease in left ventricular mass index (LVMI), delay in death).

V. REFERENCES

1. Lumizyme [package insert]. Cambridge, MA: Genzyme Corporation; March 2023.